in this issue
Markets :: Fine Chemicals/Biotech :: Industrial Biotech
Lonza Signs Manufacturing Deal with Biopharma Firm
11:31 AM MDT | June 26, 2009
Lonza says it has signed a deal to produce therapeutic monoclonal antibody Anthim for biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ). Anthim, which is in late-stage development, can be used to treat anthrax infection. Lonza says it will provide process development services and manufacturing capacity, using its GS Gene Expression System, under the deal. Elusys develops antibody therapeutics for treatment of infectious disease. Elusys has been active in the development of bio-warfare countermeasures since 2001 and has worked with the U.S. government...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee